Zoetis Inc. (NYSE:ZTS) Shares Acquired by Cape ANN Savings Bank

Cape ANN Savings Bank increased its holdings in Zoetis Inc. (NYSE:ZTSFree Report) by 6.8% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 4,910 shares of the company’s stock after buying an additional 314 shares during the period. Cape ANN Savings Bank’s holdings in Zoetis were worth $922,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Blue Bell Private Wealth Management LLC lifted its stake in shares of Zoetis by 222.5% in the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after purchasing an additional 89 shares during the period. Independence Bank of Kentucky grew its holdings in shares of Zoetis by 371.4% in the fourth quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after purchasing an additional 130 shares during the period. Private Wealth Management Group LLC purchased a new stake in shares of Zoetis in the fourth quarter valued at about $33,000. Ramirez Asset Management Inc. purchased a new stake in shares of Zoetis in the third quarter valued at about $35,000. Finally, Gladius Capital Management LP purchased a new stake in shares of Zoetis in the fourth quarter valued at about $40,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ZTS. HSBC dropped their price objective on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. Stifel Nicolaus dropped their price objective on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, April 30th. StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Piper Sandler reaffirmed an “overweight” rating and issued a $195.00 target price (down previously from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Finally, The Goldman Sachs Group decreased their target price on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a research report on Monday, May 6th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, Zoetis presently has an average rating of “Buy” and a consensus target price of $211.75.

Get Our Latest Analysis on Zoetis

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 923 shares of the firm’s stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $151.17, for a total value of $139,529.91. Following the sale, the executive vice president now owns 14,800 shares of the company’s stock, valued at $2,237,316. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Zoetis Trading Up 0.2 %

NYSE ZTS traded up $0.32 during trading hours on Monday, reaching $170.87. The company had a trading volume of 1,798,664 shares, compared to its average volume of 2,959,403. The stock has a 50-day moving average of $165.85 and a 200 day moving average of $179.50. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The company has a current ratio of 3.33, a quick ratio of 1.94 and a debt-to-equity ratio of 1.30. The stock has a market capitalization of $77.97 billion, a P/E ratio of 32.92, a price-to-earnings-growth ratio of 2.65 and a beta of 0.89.

Zoetis (NYSE:ZTSGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.04. The business had revenue of $2.19 billion for the quarter, compared to analysts’ expectations of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The business’s quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.31 earnings per share. As a group, research analysts anticipate that Zoetis Inc. will post 5.76 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 4th. Stockholders of record on Thursday, July 18th will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, July 18th. This represents a $1.73 annualized dividend and a dividend yield of 1.01%. Zoetis’s dividend payout ratio is presently 33.14%.

Zoetis Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Read More

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.